^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^Hacker BM, Tomlinson JE, Wayman GA, Sultana R, Chan G, Villacres E, Disteche C, Storm DR (Apr 1999). "Cloning, chromosomal mapping, and regulatory properties of the human type 9 adenylyl cyclase (ADCY9)". Genomics. 50 (1): 97–104.
doi:
10.1006/geno.1998.5293.
PMID9628827.
Paterson JM, Smith SM, Harmar AJ, Antoni FA (1995). "Control of a novel adenylyl cyclase by calcineurin". Biochem. Biophys. Res. Commun. 214 (3): 1000–8.
doi:
10.1006/bbrc.1995.2385.
PMID7575502.
Barcova M, Speth C, Kacani L, et al. (1999). "Involvement of adenylate cyclase and p70(S6)-kinase activation in IL-10 up-regulation in human monocytes by gp41 envelope protein of human immunodeficiency virus type 1". Pflügers Arch. 437 (4): 538–46.
doi:
10.1007/s004240050815.
PMID10089566.
S2CID7620262.
Toyota T, Hattori E, Meerabux J, et al. (2002). "Molecular analysis, mutation screening, and association study of adenylate cyclase type 9 gene (ADCY9) in mood disorders". Am. J. Med. Genet. 114 (1): 84–92.
doi:
10.1002/ajmg.10117.
PMID11840511.
Ludwig MG, Seuwen K (2003). "Characterization of the human adenylyl cyclase gene family: cDNA, gene structure, and tissue distribution of the nine isoforms". J. Recept. Signal Transduct. Res. 22 (1–4): 79–110.
doi:
10.1081/RRS-120014589.
PMID12503609.
S2CID36697419.
Small KM, Brown KM, Theiss CT, et al. (2004). "An Ile to Met polymorphism in the catalytic domain of adenylyl cyclase type 9 confers reduced beta2-adrenergic receptor stimulation". Pharmacogenetics. 13 (9): 535–41.
doi:
10.1097/00008571-200309000-00002.
PMID12972952.